series-b
Stage
1
Investors
About
Kahr Medical Ltd develops immunotherapeutic fusion proteins called Dual Signalling Proteins (DSP) that target cancer cells specifically to engage the immune system in attacking tumors while sparing normal cells.
Explore Kahr Medical Ltd's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.